For instance, in the first quarter of FY16, licensing revenues contributed to Rs 19 crore and the company expects to see this increasing going forward.

The company's net sales rose 15 per cent at Rs 857 crore for the period under review as compared to Rs 742 crore in the year-ago period, Biocon said in a statement.

Suven has recorded 50 per cent compound annual growth rate (CAGR) since 2011. Its total income were up from Rs 152.25 crore in 2010/11 to Rs 529.8 crore in 2014/15, which is marginally higher than 2013/14.

Mylan is strongly resisting an unsolicited $40 billion bid by Israel-based Teva to acquire Mylan. But on the other hand, it is also pursuing its own $32.7 billion bid to acquire Ireland-based maker of cough and cold remedies.

The deal also covers the sale by Aspen's Mauritius unit of a portfolio of six branded prescription drugs to Strides' Singapore business.

A little over three years ago, Strides Arcolab made news by selling its 94 per cent stake in Ascent Pharmahealth, its subsidiary with operations in Australia and Southeast Asia, to Watson Pharmaceuticals (now Actavis Inc) for $393 million.

The transaction is expected to close by the end of the second quarter of FY16.

Shares of Godrej Properties surged over 6 per cent on Thursday after the company said it sold over 200 apartments, with an area over 400,000 sq ft, in just three weeks after the launch of its new residential project in Gurgaon.

Industry observers feel it would take a lot of effort for Wockhardt to regain its glory and it won't be easy considering the company's business mix, strategies and product portfolio.

Teva had made an offer to acquire all outstanding shares of Mylan at $ 82 per share - 50 per cent in cash and another 50 per cent in stock.

Piramal Enterprises has signed a definitive agreement to sell its clinical research division known as 'Piramal Clinical Research' to Indoco Remedies on a going concern basis for cash, the company said in a filing to BSE.

The merger deal, once consummated, would create India's largest and world's fifth-biggest drug maker.

The government sought to put controls on drugmakers when it came to pricing of essential drugs, including those for common cough and cold as also for cancer and other diseases.

The financial services sector has emerged as the most favoured since May this year by attracting Rs 11,024 crore till October 15 as against an outflow of Rs 5,666 crore in this period previous year.

The second Business Today-YES Bank Emerging Companies Excellence Survey unearths gems that could go far.

Featuring news on Facebook, J. Jayalalithaa, Amma brand, Vishal Sikka, Infosys, Amazon, Jeff Bezos, Mark Zuckerberg and more.

The new age CFO must now realise that he is no longer expected to linger in the background and surface every time the results are to be announced.

This is probably the first instance where CCI has ordered a public scrutiny of a proposed merger and acquisition (M&A) deal to ensure compliance to fair trade regulations.

For CCI, this is one of the biggest merger and acquisition deal in the pharma sector and any decision in this case is expected to have wider implications.

The Competition Commission of India would take a final view on the deal after receiving details from them and could seek more information if it is not satisfied with the responses.